SCHEMBL13627908

SCHEMBL13627908

O=C1/C(=N\O)c2cc(Br)ccc2N1Cc1cccc(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.58
CA2 P00918 6/20 0.58
CA9 Q16790 5/20 0.58
CA12 O43570 4/20 0.58
ALDH1A1 P00352 6/20 0.52
ALDH3A1 P30838 6/20 0.52
ALDH2 P05091 3/20 0.52
UBE2N P61088 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
UCHL1 P09936 2/20 0.48
UCHL3 P15374 2/20 0.48
ACHE P22303 1/20 0.48
CA4 P22748 1/20 0.47
CA7 P43166 1/20 0.47
TRPA1 O75762 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627946 0.90 UBE2N (0.56) CA1CA2CA9CA12ALDH1A1
SCHEMBL13627901 0.87 ACHE (0.58) CA1CA2CA9CA12ALDH1A1
SCHEMBL13627900 0.87 ALDH1A1 (0.69) CA1CA2CA9CA12ALDH1A1
SCHEMBL13627932 0.86 CA1 (0.59) CA1CA2CA9CA12ALDH1A1
SCHEMBL13627923 0.86 UBE2N (0.52) CA1CA2CA9CA12ALDH1A1
SCHEMBL13627906 0.86 ALDH1A1 (0.52) CA1CA2CA9CA12ALDH1A1
SCHEMBL13627897 0.85 UBE2N (0.63) CA1CA2CA9CA12ALDH1A1
SCHEMBL13627915 0.82 CASP1 (0.56) CA1CA2CA9CA12ALDH1A1
SCHEMBL13627936 0.82 TRPA1 (0.62) ALDH1A1ALDH3A1ALDH2TRPA1MAPT
SCHEMBL13627948 0.81 TRPA1 (0.48) CA1CA2CA9CA12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CA1 3628/4885CA2 3142/4885CA9 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.